A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02372227 |
|
Recruitment Status :
Terminated
First Posted : February 26, 2015
Last Update Posted : January 30, 2017
|
Sponsor:
Verastem, Inc.
Information provided by (Responsible Party):
Verastem, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | October 2015 |
| Actual Study Completion Date : | October 2015 |